Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The smallpox vaccine Vaccinia was successfully used to eradicate smallpox, but although very effective, it was a very reactogenic vaccine and responsible for the deaths of one or two people per million vaccinated. Modified Vaccinia virus Ankara (MVA) is a replication-deficient and attenuated derivative, also used in the smallpox eradication campaign and now being developed as a recombinant viral vector to produce vaccines against infectious diseases and cancer. Many clinical trials of these new vaccines have been conducted, and the findings of these trials are reviewed here. The safety of MVA is now well documented, immunogenicity is influenced by the dose and vaccination regimen, and information on the efficacy of MVA-vectored vaccines is now beginning to accumulate.

Original publication

DOI

10.1016/j.vaccine.2013.03.020

Type

Journal article

Journal

Vaccine

Publication Date

06/09/2013

Volume

31

Pages

4241 - 4246

Keywords

Clinical safety, Efficacy, Immunogenicity, Poxvirus, Vaccine, Animals, Genetic Vectors, Humans, Malaria, Smallpox, Smallpox Vaccine, Vaccination, Vaccines, Attenuated, Vaccinia virus, Viral Vaccines